Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialEurope PMCOpen access

Therapeutic Effects of Stromal Stem Cells Derived from Ovarian Tissue in a Cyclophosphamide-Induced Rat Model of Ovarian Failure

Akgün M., Ünal MS., Altınbaşak F., Önder E., Tan S.

Randomized Controlled Trial with a reported sample of 6 on Face & Skin, Hair & Scalp, published in Reprod Sci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Reprod Sci (2026)
Reported sample size
6
Source database
Europe PMC
PMID
42056651
PMCID
PMC13230237
DOI
10.1007/s43032-026-02114-7

Abstract (original English)

Chemotherapeutic agents used in cancer treatment cause damage to both oocytes and granulosa cells, resulting in follicle loss and consequently premature ovarian failure. In this study the animals were randomly assigned to three groups: control (n = 6), chemotherapy (n = 6), and stem cell treatment (n = 6). Ovarian failure was induced in the chemotherapy and stem cell groups by intraperitoneal administration of cyclophosphamide (200 mg/kg) on days 1 and 8. Ovarian stromal stem cells (OSSCs) were isolated from the ovaries of 4-week-old donor rats (n = 2) using the explant culture method. On day 9, isolated stromal cells were transplanted bilaterally into the ovaries of rats in the stem cell group. Surface markers were analyzed by flow cytometry in OSSCs, and their adipogenic, osteogenic, and chondrogenic differentiation potentials were evaluated under appropriate in vitro conditions. The number of follicles and the morphological features of the ovarian tissue were histologically examined using hematoxylin and eosin (H&E) staining. Caspase 3 expression in ovarian tissue was analyzed using TUNEL and immunohistochemistry methods. Flow cytometry analysis of isolated ovarian stromal cells showed that CD54, CD90 and CD45 surface markers were expressed, while CD29 was expressed at a lower level. These findings confirmed the ability of OSSCs to differentiate into adipogenic, osteogenic,

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
OvaryCells, CulturedStromal CellsAnimalsRatsRats, Sprague-DawleyDisease Models, AnimalCyclophosphamideAntineoplastic Agents, AlkylatingApoptosis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research